Illumina 3D Deep Brain Stimulation for Parkinson's Disease

This trial explores a new method to help individuals with Parkinson's disease manage motor symptoms, such as walking and finger movements, using an automated deep brain stimulation (DBS) system called Illumina 3D. Researchers aim to determine if this system can improve symptoms more effectively than standard DBS settings. Participants will experience different DBS settings during the trial but will return to their usual settings afterward. This trial is suitable for those who have recently had DBS implanted and are ready for initial activation. The trial involves short-term testing, requiring no long-term commitment. As an unphased trial, it offers participants the chance to contribute to innovative research that could enhance future treatment options for Parkinson's disease.

The trial may require you to stop taking your current medications during research visits, as participants must be willing to withdraw from their clinical medication regimen if necessary.

Studies have shown that deep brain stimulation (DBS) is generally well-tolerated by people with Parkinson's disease. Research indicates that DBS effectively improves motor symptoms, addressing the movement and control issues often experienced by those with Parkinson's. Illumina 3D, a new automated DBS method, is currently undergoing tests for safety and effectiveness.

Previous findings suggest that DBS, including the Illumina 3D method, can be safely used in patients. Side effects are rare but may include infection, bleeding, or device-related issues, typically linked to the surgery rather than the stimulation itself. In trials, patients using DBS have not shown significant safety concerns specific to the Illumina 3D method.

Researchers are excited about Illumina 3D Deep Brain Stimulation for Parkinson's Disease because it offers a new approach to managing symptoms. Unlike traditional deep brain stimulation, which uses a consistent amplitude, Illumina 3D allows for adjustments in amplitude, providing more personalized treatment options. This flexibility could potentially lead to more effective symptom control and reduce side effects. By fine-tuning the stimulation levels, this method aims to optimize patient outcomes, making it a promising development in Parkinson's care.

Research has shown that deep brain stimulation (DBS) helps manage movement problems in people with Parkinson's disease, improving movement and reducing shaking. In this trial, participants will experience different DBS conditions, including the Illumina 3D Deep Brain Stimulation. This new tool from Boston Scientific automatically adjusts DBS settings to enhance these benefits. Studies have found that DBS leads to improved results when used with advanced programming like Illumina 3D. This technology uses images to customize treatment for each person, potentially improving their quality of life.²³⁴⁵⁶